Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cidara Therapeutics (CDTX) Return on Capital Employed: 2018-2025

Historic Return on Capital Employed for Cidara Therapeutics (CDTX) over the last 8 years, with Sep 2025 value amounting to -0.45%.

  • Cidara Therapeutics' Return on Capital Employed rose 60.00% to -0.45% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.45%, marking a year-over-year increase of 60.00%. This contributed to the annual value of -1.93% for FY2024, which is 459.00% down from last year.
  • Latest data reveals that Cidara Therapeutics reported Return on Capital Employed of -0.45% as of Q3 2025, which was down 20.83% from -0.38% recorded in Q2 2025.
  • Cidara Therapeutics' 5-year Return on Capital Employed high stood at 9.36% for Q4 2023, and its period low was -13.01% during Q2 2022.
  • Moreover, its 3-year median value for Return on Capital Employed was -0.71% (2023), whereas its average is 0.57%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first crashed by 1,116bps in 2022, then skyrocketed by 1,291bps in 2023.
  • Cidara Therapeutics' Return on Capital Employed (Quarterly) stood at -1.44% in 2021, then tumbled by 69bps to -2.13% in 2022, then spiked by 1,149bps to 9.36% in 2023, then slumped by 1,063bps to -1.27% in 2024, then skyrocketed by 60bps to -0.45% in 2025.
  • Its Return on Capital Employed was -0.45% in Q3 2025, compared to -0.38% in Q2 2025 and -1.25% in Q1 2025.